EpimAb With a goal of developing bispecific antibodies for up to three undisclosed target pairs, EpimAb Biotherapeutics and Almirall entered into a license agreement. Under the terms of the agreement, Almirall gains exclusive global rights to utilize EpimAb's FIT-Ig® platform technology for bispecific antibody development. Absci We joined forces with Absci Corporation to harness generative AI for developing and commercializing novel therapeutics targeting chronic dermatological diseases. This collaboration marks our first foray into de novo AI drug creation, leveraging Absci's 'zero-shot' generative AI and Integrated Drug Creation™ platform, aiming to deliver transformative medicines. This partnership is a significant milestone in AI-driven drug development. etherna Together with etherna, we have established a strategic alliance to pioneer mRNA-based therapies for serious skin conditions, including non-melanoma skin cancer. While joint research efforts are planned, Almirall will lead the clinical and commercial stages. Ichnos Sciences ALM27134Autoimmune diseases Kaken Pharmaceutical EfinaconazoleOnychomycosis Eli Lilly and Company EBGLYSS® (lebrikizumab)Atopic dermatitis Sun Pharma Ilumetri® (tildrakizumab)Psoriasis Athenex Klisyri® (tirbanibulin)Actinic keratosis MC2 Therapeutics Wynzora® (CAL/BDP cream)Psoriasis Paratek Seysara® (sarecycline)Acne Simcere SIM0278 All indications Evotec Severe skin diseases Ablexis / AlivaMab Discovery Services Antibody drug discovery and development Assets Technology platforms Academic